The difficulties with using the standard therapy, warfarin, in this indication have led to the development of the novel oral anticoagulants. Uptake of the two marketed novel therapies, Pradaxa and Xarelto, has been slower than expected. However, the pipeline drug Eliquis has the potential to expand oral anticoagulant usage beyond its traditional patient population.
Features and benefits
Report Details:
Published: August 2012
No. of Pages: 68
Price:Single User License:US$11400 Corporate User License:US$28500
Highlights
Despite the difficulties with warfarin usage, the widely genericized drug is holding its own against the novel oral anticoagulants due to its much lower price point in comparison to branded Pradaxa and Xarelto.
The marketed novel oral anticoagulants, Pradaxa and Xarelto, have faced slower than expected uptake due to physician uncertainty over bleeding risks in a clinical setting and the lack of an antidote.
The pipeline candidate Eliquis, which is expected in Q1 2013, has the potential to become best-in-class based on strong Phase III efficacy and safety trial data.
Your key questions answered
Features and benefits
- Understand Datamonitor’s independent appraisal of marketed oral anticoagulant brands and key pipeline agents indicated for treating SPAF.
- Illustrate how pipeline and marketed oral anticoagulants compare in terms of clinical and commercial attributes.
- Review important clinical developments for the key pipeline agents with analysis of the latest clinical trial data.
- Determine to what extent the key pipeline drug Eliquis (apixaban) satisfies the main clinical unmet needs in SPAF.
Report Details:
Published: August 2012
No. of Pages: 68
Price:Single User License:US$11400 Corporate User License:US$28500
Highlights
Despite the difficulties with warfarin usage, the widely genericized drug is holding its own against the novel oral anticoagulants due to its much lower price point in comparison to branded Pradaxa and Xarelto.
The marketed novel oral anticoagulants, Pradaxa and Xarelto, have faced slower than expected uptake due to physician uncertainty over bleeding risks in a clinical setting and the lack of an antidote.
The pipeline candidate Eliquis, which is expected in Q1 2013, has the potential to become best-in-class based on strong Phase III efficacy and safety trial data.
Your key questions answered
- How are the marketed oral anticoagulants positioned in SPAF?
- How will the pipeline candidates impact on the way SPAF is managed?
- What are the comparative strengths and weaknesses of the key oral anticoagulants and pipeline candidates?
- How has the clinical development of an antidote to the novel oral anticoagulants progressed?
- What impact will the novel oral anticoagulants have on the current therapy options, warfarin and aspirin?
